| |
| | Preventing Tetanus, Diphtheria, and Pertussis Among Adolescents: Use of Tetanus Toxoid, Reduced Diphtheria Toxoid and ... |
 | | In 1991, less reactogenic pediatric acellular pertussis vaccine (diphtheria and tetanus toxoids and acellular pertussis vaccine [DTaP]) was first licensed for use in children for the fourth and fifth doses of the 5-dose childhood vaccination series in the United States (21,22), and in 1996, pediatric DTaP was licensed for the first three infant doses (1). |
 | | The tetanus and diphtheria toxoid composition of Tdap is similar to licensed adult formulations of Td (Appendix A). |
 | | In addition, high pre-existing antibody titers to tetanus or diphtheria toxoids in children, adolescents, and adults primed with these antigens might be associated with increased rates of local reactions to booster doses of tetanus or diphtheria toxoid--containing vaccines (26,108,111,112). |
| www.cdc.gov /mmwr/preview/mmwrhtml/rr5503a1.htm (15833 words) |
|